<DOC>
	<DOCNO>NCT01474551</DOCNO>
	<brief_summary>The purpose study find effect , good and/or bad , vemurafenib patient melanoma . Specifically , investigator want know well vemurafenib shrink melanoma . The investigator also want find well vemurafenib improve well patient function .</brief_summary>
	<brief_title>Vemurafenib ( R05185426 ) Poor Performance Status Patients With Unresectable Locally Advanced Metastatic Melanoma Harboring V600E/K Mutation</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Age &gt; 18 year old . Histologic proof melanoma review confirm MSKCC . A confirm EBRAFV600E KBRAFV600K mutation . Stage IV melanoma , advanced stage III curable surgery . Patients active CNS metastasis allow study . Measurable disease RECIST v1.1 . ECOG performance status 3 4 . The basis grade performance strict ; must clear justification performance status grade ( e.g . patient confine bed &gt; 50 % time , carry ADLs , otherwise disabled burden disease require supplemental O2 ) . Patients must able swallow pill Adequate hematologic , hepatic renal function define follow : Absolute Neutrophil Count ≥ 1.0 x 109/L Hemoglobin ≥8.0g/dL , occasional transfusion acceptable vemurafenib significant hematologic toxicity . Total bilirubin ≤2.0x upper limit normal , ≤3.0x upper limit normal patient Gilbert 's Syndrome . Alkaline phosphatase ≤2.0x upper limit normal . AST ALT ≤2.0x upper limit normal . Serum creatinine ≤ 1.5x upper limit normal . Uveal melanoma primary . Concurrent chemotherapy , immunotherapy , radiotherapy . Prior treatment RAF inhibitor . Other prior chemotherapy , immunotherapy , radiotherapy allow include prior treatment MEK inhibitor Patients must complete recovery adverse event toxicity prior cancerdirected therapy . Pregnant lactating woman . A second active malignancy . Prior malignancy allow long patient know free disease least 2 year . Patients indolent Bcell malignancy eligible . QTc interval &gt; 500 msec .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Vemurafenib</keyword>
	<keyword>skin cancer</keyword>
	<keyword>Stage IV</keyword>
	<keyword>advanced stage III</keyword>
	<keyword>11-091</keyword>
</DOC>